Skip to main content
    I

    Immuneering Corp (IMRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.52
    -0.19 (-5.12%)

    Market Cap: $240.27M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Immuneering Corp (IMRX) Financials: Revenue, Profit and Cash Flow

    Updated Aug 5, 2026. Financial statements from company filings, amounts in US dollars.

    Immuneering reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$56.02M, operating cash flow was -$45.34M and free cash flow was -$45.49M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of -$17.27M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $59.38M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0-100.0%N/AN/AN/A
    Dec 2022$316.95K-84.8%50.1%-16325.8%-15937.3%
    Dec 2021$2.08M-10.0%44.6%-1629.2%-1612.3%
    Dec 2020$2.31M+20.4%44.6%-739.0%-737.2%
    Dec 2019$1.92MN/A36.3%-327.7%-401.6%
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$0$0$0$316.95K$2.08M$2.31M$1.92M
    Cost of revenue$0$0$0$158.12K$1.15M$1.28M$1.22M
    Gross profit$0$0$0$158.83K$926.89K$1.03M$696.74K
    Research and development$42.05M$47.96M$41.62M$36.27M$26.54M$15.00M$4.28M
    Operating income-$59.38M-$64.07M-$58.41M-$51.74M-$33.89M-$17.08M-$6.29M
    Net income-$56.02M-$61.04M-$53.47M-$50.51M-$33.54M-$17.04M-$7.71M
    EBITDA-$59.18M-$63.95MN/A-$51.42M-$33.72M-$17.00MN/A
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$0$0$0$0$0$0$726.33K$0$0$0-$94.42M$0
    Gross profit$0$0-$612.73K$0$0$0-$174.65K$0$0$0-$185.22K$0
    Operating income-$19.00M-$15.34M-$13.75M-$15.38M-$14.76M-$15.48M-$18.56M-$15.27M-$14.91M-$15.33M-$16.30M-$13.93M
    Net income-$17.27M-$13.46M-$11.58M-$14.96M-$14.43M-$15.05M-$18.05M-$14.60M-$14.08M-$14.31M-$15.08M-$12.60M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $397.10K by $128.25M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$231.99M$52.71M$102.58M$122.37M$166.70M$38.42M$14.10M
    Current assets$176.25M$39.59M$89.08M$108.75M$152.33M$37.73M$14.06M
    Cash and equivalents$128.65M$36.14M$59.41M$72.64M$74.89M$37.09M$13.78M
    Total liabilities$13.50M$11.33M$12.01M$12.52M$10.72M$2.80M$20.63M
    Short-term debt$397.10K$338.44K$300.11K$378.72K$274.04K$76.32KN/A
    Shareholder equity$218.48M$41.39M$90.58M$109.85M$155.98M-$22.48M-$6.53M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$202.06M$214.81M$231.99M$241.06M$40.06M$50.68M$52.71M$68.56M$77.09M$87.98M$102.58M$113.88M
    Total liabilities$11.32M$8.29M$13.50M$13.08M$11.12M$8.84M$11.33M$10.84M$10.78M$9.26M$12.01M$9.86M
    Cash and equivalents$41.32M$47.32M$128.65M$227.56M$26.36M$35.87M$36.14M$45.21M$59.73M$66.29M$59.41M$68.04M
    Shareholder equity$190.74M$206.52M$218.48M$227.98M$28.94M$41.84M$41.39M$57.72M$66.31M$78.72M$90.58M$104.02M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$45.34M-$55.00M-$48.97M-$44.10M-$30.85M-$14.62M-$4.44M
    Capital expenditures$142.23K$84.88K$342.75K$742.48K$60.79K$53.41K$20.53K
    Free cash flow-$45.49M-$55.08M-$49.31M-$44.84M-$30.91M-$14.67M-$4.46M
    Share repurchases$3.73M$40.99K$203.77K$281.38K$0$0N/A
    Investing cash flow-$88.74M$26.43M$7.30M$41.83M-$75.62M-$53.41K-$20.53K
    Financing cash flow$226.58M$5.30M$28.44M$19.00K$144.26M$37.98M$17.17M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$16.50M-$18.43M-$9.84M-$11.98M-$9.45M-$14.08M-$14.51M-$13.47M-$11.53M-$15.49M-$11.78M-$12.03M
    Capital expenditures$27.37K$79.93K$123.91K$7.25K$2.12K$8.95K$9.36K$5.27K$32.77K$37.48K$170.92K$57.15K
    Free cash flow-$16.53M-$18.51M-$9.96M-$11.98M-$9.45M-$14.09M-$14.52M-$13.48M-$11.56M-$15.53M-$11.95M-$12.08M
    Last 12 quarters

    Frequently Asked Questions About IMRX

    What is Immuneering's annual revenue?

    Immuneering reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Immuneering profitable?

    No. Immuneering reported net income of -$56.02M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does IMRX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$45.34M minus capital expenditures of $142.23K produced free cash flow of -$45.49M.

    How much debt does Immuneering have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $397.10K and cash and equivalents of $128.65M.